Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147609 | 0.86 | PARP1 (0.41) | KMT2AMEN1TDP1RAB9A | |
| SCHEMBL1694653 | 0.84 | ALOX5AP (0.43) | TDP1KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL1695353 | 0.81 | KDM4E (0.42) | KMT2AMEN1KDM4ERAB9AHTT | |
| SCHEMBL1694667 | 0.78 | ALDH1A1 (0.40) | TDP1KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL1694712 | 0.76 | PIK3CD (0.41) | — | |
| SCHEMBL1695345 | 0.73 | SMN1; SMN2 (0.42) | KMT2AMEN1TDP1KDM4ERAB9A | |
| SCHEMBL1694663 | 0.73 | ACACB (0.42) | KMT2AMEN1RAB9A | |
| SCHEMBL14827191 | 0.72 | ACACB (0.42) | KMT2AMEN1RAB9A | |
| SCHEMBL10761618 | 0.71 | TACR3 (0.53) | KMT2AMEN1TDP1KDM4EALDH1A1 | |
| SCHEMBL24951562 | 0.70 | KDM4E (0.47) | TDP1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588467-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2012003274-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, BCL9 | KMT2A 625/4885MEN1 1095/4885TDP1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.